ClinicalTrials.gov
public full text
Public Domain
Nabilone for Agitation in Frontotemporal Dementia
The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and primary progressive aphasia). The study population is defined as patients with probable Frontotemporal Dementia that meet the International Psychogeriatric Association criteria for agitation in cognitive disorders.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia#1112412
- Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type#864130
- Pharmacological management in frontotemporal dementia and patient outcomes: a retrospective cohort study using the TriNetX platform.#1000970
- Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)#1007893
- Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort#1157670
Record · ID 908001
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive